Nabriva Therapeutics AG (NASDAQ:NBRV) major shareholder Hbm Healthcare Investments (Ca sold 6,585 shares of the firm’s stock in a transaction on Friday, July 28th. The stock was sold at an average price of $10.51, for a total transaction of $69,208.35. Following the completion of the sale, the insider now owns 2,391,177 shares in the company, valued at $25,131,270.27. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Hbm Healthcare Investments (Ca also recently made the following trade(s):

  • On Monday, August 7th, Hbm Healthcare Investments (Ca sold 17,790 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.50, for a total transaction of $186,795.00.
  • On Tuesday, August 8th, Hbm Healthcare Investments (Ca sold 19,803 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.50, for a total transaction of $207,931.50.
  • On Monday, July 24th, Hbm Healthcare Investments (Ca sold 160 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.50, for a total transaction of $1,680.00.
  • On Thursday, July 20th, Hbm Healthcare Investments (Ca sold 44,231 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.50, for a total transaction of $464,425.50.
  • On Tuesday, July 18th, Hbm Healthcare Investments (Ca sold 69,854 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.51, for a total transaction of $734,165.54.
  • On Thursday, July 13th, Hbm Healthcare Investments (Ca sold 57,175 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.53, for a total transaction of $602,052.75.
  • On Friday, July 7th, Hbm Healthcare Investments (Ca sold 2,695 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.52, for a total transaction of $28,351.40.
  • On Friday, June 30th, Hbm Healthcare Investments (Ca sold 1,775 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.94, for a total transaction of $19,418.50.
  • On Monday, July 3rd, Hbm Healthcare Investments (Ca sold 13,127 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.94, for a total transaction of $143,609.38.
  • On Thursday, June 29th, Hbm Healthcare Investments (Ca sold 8,558 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.96, for a total transaction of $93,795.68.

Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) traded down 0.23% during trading on Friday, reaching $8.81. 3,730 shares of the company traded hands. The stock’s market capitalization is $236.44 million. The company has a 50-day moving average of $10.19 and a 200-day moving average of $10.38. Nabriva Therapeutics AG has a 12 month low of $3.52 and a 12 month high of $12.75.

Nabriva Therapeutics AG (NASDAQ:NBRV) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($5.83) by $5.29. The company had revenue of $1.05 million during the quarter, compared to the consensus estimate of $1.34 million. Analysts forecast that Nabriva Therapeutics AG will post ($2.40) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Nabriva Therapeutics AG (NBRV) Major Shareholder Hbm Healthcare Investments (Ca Sells 6,585 Shares” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/19/hbm-healthcare-investments-ca-sells-6585-shares-of-nabriva-therapeutics-ag-nbrv-stock-updated-updated.html.

NBRV has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Nabriva Therapeutics AG in a report on Friday, May 12th. Cantor Fitzgerald set a $16.00 price objective on shares of Nabriva Therapeutics AG and gave the stock a “buy” rating in a report on Thursday, May 11th. Zacks Investment Research raised shares of Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a report on Saturday, May 27th. ValuEngine raised shares of Nabriva Therapeutics AG from a “sell” rating to a “hold” rating in a report on Saturday, June 24th. Finally, Wedbush reissued an “outperform” rating and set a $13.00 price target on shares of Nabriva Therapeutics AG in a report on Monday, May 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $15.43.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Royal Bank of Canada boosted its position in Nabriva Therapeutics AG by 19.6% in the second quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock worth $553,000 after buying an additional 8,650 shares during the period. Nationwide Fund Advisors boosted its position in Nabriva Therapeutics AG by 4.6% in the second quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock worth $2,032,000 after buying an additional 7,924 shares during the period. Almanack Investment Partners LLC. boosted its position in Nabriva Therapeutics AG by 482.2% in the second quarter. Almanack Investment Partners LLC. now owns 907,183 shares of the biotechnology company’s stock worth $1,633,000 after buying an additional 751,366 shares during the period. Wellington Management Group LLP boosted its position in Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock worth $25,830,000 after buying an additional 193,951 shares during the period. Finally, Renaissance Technologies LLC bought a new position in Nabriva Therapeutics AG during the fourth quarter worth approximately $103,000. 56.65% of the stock is owned by hedge funds and other institutional investors.

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Insider Buying and Selling by Quarter for Nabriva Therapeutics AG (NASDAQ:NBRV)

Receive News & Stock Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related stocks with our FREE daily email newsletter.